One of the most persistent challenges in modern medicine is not simply that certain bacteria have developed resistance to antibiotics. It is that resistant bacteria can extend that protection to neighboring strains that would otherwise be vulnerable, creating a kind of communal defense that makes infections dramatically harder to treat. A new study published in the journal eLife has identified a way to dismantle both mechanisms at once, opening a potential path toward restoring the effectiveness of drugs that resistant bacteria have long been able to neutralize.
The research, conducted by a team at the University of Texas at Austin in collaboration with scientists at Imperial College London, centers on a protein-folding system that resistant bacteria rely on to keep their resistance enzymes functional. By disrupting that system, researchers were able to sensitize bacteria to antibiotics they had previously been able to withstand, while simultaneously eliminating their ability to shield nearby microbes.
Antibiotic resistance in the real world
Most research into drug-resistant bacteria focuses on a single pathogen in a controlled laboratory setting. The reality of clinical infections is considerably messier. The majority of serious infections involve multiple bacterial species coexisting and interacting in ways that compound the difficulty of treatment. Resistant strains can degrade antibiotics in their immediate environment, lowering drug concentrations enough to allow sensitive neighboring bacteria to survive alongside them. This process, known as cross-protection, is particularly well documented in the lung infections associated with cystic fibrosis.
The research team designed their study to reflect that complexity, working with synthetic communities of two bacterial species commonly found together in cystic fibrosis-related lung infections. One species is the most prevalent pathogen in that context and is typically treated with a class of antibiotics called beta-lactams, which includes penicillins and cephalosporins. The other species is resistant to nearly all available antibiotics, including beta-lactams, and produces enzymes that actively break those drugs down in the surrounding environment, providing cover for both itself and its neighbors.
How the mechanism works and what it means
The research team used two approaches to test whether disrupting the protein-folding system could reverse this dynamic. The first involved genetically removing the relevant folding gene from bacterial DNA. The second involved introducing chemical inhibitors that could achieve the same effect without any genetic modification. Both methods produced the same result: resistance enzymes stopped functioning, bacteria became vulnerable to antibiotics, and the cross-protection effect disappeared.
The chemical inhibitor finding is particularly significant from a drug development standpoint. It demonstrates that resistance can be reversed through compounds rather than genetic intervention, which is a far more practical path toward clinical application. The researchers also tested their approach in infected wax moth larvae and in mixed bacterial communities, finding consistent results that suggest the mechanism holds under conditions closer to those found in living organisms.
Implications beyond cystic fibrosis
The protein-folding system targeted in this research is not unique to the bacterial species studied. Similar survival mechanisms exist across a wide range of bacterial pathogens, which means the implications of the finding extend well beyond cystic fibrosis treatment. Researchers believe the approach could inform strategies for addressing drug-resistant infections more broadly, at a moment when resistance to available antibiotics has become one of the most urgent challenges in global public health.
The study was supported by a range of funding sources including the National Institute of Allergy and Infectious Diseases, the U.K. Medical Research Council, and several university and foundation partners. Further research will be needed to translate the laboratory findings into clinical treatments, but the discovery represents a meaningful step toward restoring the arsenal of drugs that resistance has steadily eroded.
